CSIMarket
 
Cns Pharmaceuticals Inc   (CNSP)
Other Ticker:  
 
 
Price: $0.3750 $0.00 -0.794%
Day's High: $0.378 Week Perf: 3.65 %
Day's Low: $ 0.35 30 Day Perf: 49.4 %
Volume (M): 27 52 Wk High: $ 4.40
Volume (M$): $ 10 52 Wk Avg: $1.47
Open: $0.38 52 Wk Low: $0.23



 Market Capitalization (Millions $) 2
 Shares Outstanding (Millions) 4
 Employees -
 Revenues (TTM) (Millions $) 0
 Net Income (TTM) (Millions $) -19
 Cash Flow (TTM) (Millions $) -6
 Capital Exp. (TTM) (Millions $) 0

Cns Pharmaceuticals Inc
CNS Pharmaceuticals Inc is a biotechnology company focused on the development of novel treatments for central nervous system (CNS) disorders. The company aims to address unmet medical needs in diseases such as glioblastoma multiforme (GBM), an aggressive and difficult to treat form of brain cancer.

CNS Pharmaceuticals is primarily focused on the development of Berubicin, a potential breakthrough therapy for GBM. Berubicin is a potent anthracycline chemotherapy agent that has demonstrated promising results in preclinical studies and has currently entered Phase 1 clinical trials.

The company's mission is to bring innovative and effective therapies to patients suffering from CNS disorders with limited treatment options. CNS Pharmaceuticals is committed to advancing the development of Berubicin and other potential therapies through rigorous scientific research and clinical trials.


   Company Address: 2100 West Loop South Houston 77027 TX
   Company Phone Number: 946-9185   Stock Exchange / Ticker: NASDAQ CNSP
   CNSP is expected to report next financial results on March 30, 2024.


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Cns Pharmaceuticals Inc

Cns Pharmaceuticals Inc: Generating Revenue Surprises with $0.012883 Million in Q3 2023 Report

The stock market has always been a dynamic and exciting industry, and one company that has been making waves in recent times is Cns Pharmaceuticals Inc. Despite reporting a net loss in the third quarter of 2023, the company's potential cannot be overlooked. With an upcoming financial report scheduled for March 30, 2024, investors and analysts eagerly await the future prospects of this promising pharmaceutical firm.
While it is true that Cns Pharmaceuticals Inc incurred a net loss of $-4.523 million in the third quarter of 2023, it is essential to consider the bigger picture. Revenue disclosed in the same period reached an impressive $0.012883 million. These numbers demonstrate the company's ability to generate revenue and suggests that their products and services are gaining traction in the market.

Cns Pharmaceuticals Inc

Cns Pharmaceuticals Inc Faces Financial Struggles with a Net Shortfall of $4.0 Million, Sending Stock Prices Plummeting



Cns Pharmaceuticals Inc (NASDAQ: CNSP) recently disclosed its financial results for the period ending June 30, 2023, indicating a net shortfall of $4.021 million, surpassing the $3.566 million recorded in the corresponding period in the previous year. The company's revenue for the same period was $0.007802 million, suggesting a modest increase in revenue generation. These results reflect the ongoing challenges the company is facing as it strives to improve its financial performance.
Cns Pharmaceuticals Inc's financial woes have continued to impact its stock performance. In the past week alone, the company's stock experienced an 11.01% decline. As a result, the year to date performance stands at -24.06%, indicating a considerable setback for investors. Though these figures raise concerns, it is crucial to assess the company's potential and the factors that may influence its future performance.

Cns Pharmaceuticals Inc

CNS Pharmaceuticals Inc. Faces Steep Financial Losses and Declining Rankings in the Healthcare Sector

Cns Pharmaceuticals Inc, a company operating in the Healthcare sector, has reported significant financial losses over the course of the 12 months ending in the first quarter of 2023. Cumulative net losses amounted to -$17 million, resulting in a negative return on investment (ROI) of -220.94%. The negative ROI indicates that the company has lost more money than it has gained from investments, which translates to a poor overall financial performance.
Furthermore, the company's total ranking has deteriorated from 0 to 4572, compared to the fourth quarter of 2022. There are currently 894 other companies within the Healthcare sector that have a higher ROI, indicating that Cns Pharmaceuticals Inc is not performing well compared to its peers.






 

Cns Pharmaceuticals Inc's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com